There are several ongoing studies on<unk><unk>  for the prevention of venous thromboembolism (VTE).  The APEX study is a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration betrixaban with standard of care enoxaparin for the prevention of VTE in acute medically ill patients.  MARINER is a randomized, double-blind, placebo-controlled, event-driven, multicenter study in patients who are hospitalized for a specific acute medical illness and have other risk factors for VTE, which aims to evaluate rivaroxaban in the prevention of symptomatic VTE events and VTE-related deaths for a period of 45 days post-hospital discharge.
Deep vein thrombosis future or investigational therapies
Deep vein thrombosis invasive therapy
Deep vein thrombosis landmark trials in treatment
Deep vein thrombosis medical therapy
Deep vein thrombosis assessment of probability of subsequent VTE and risk scores
Deep vein thrombosis landmark trials in prevention
Deep vein thrombosis cost-effectiveness of therapy
Pulmonary embolism assessment of probability of subsequent VTE and risk scores